Hepatitis C virus genotype and viral testing, and on‐treatment monitoring: necessary or overkill?

Ekpanyapong, Sirina; Reddy, K. Rajender

doi:10.1002/9781119533481.ch7

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 7 , 8 In addition, patients with advanced disease can be at the risk of developing liver disease and HCC even though their viral infection is inactive and may require long-term monitoring of their liver disease. 9 , 10 …”

Section: Introductionmentioning

confidence: 99%

Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up

Tameshkel

Niya

Khoonsari

et al. 2021

Middle East J Dig Dis

View full text Add to dashboard Cite

BACKGROUND Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection showed the presence of resistant-associated substitutions (RASs). The aim of the present study was to carry out a follow-up of patients with baseline RASs to report the impact of RASs on DAA therapy outcome. METHODS In a cohort study, we analyzed NS5A and NS5B RASs among nine thalassemia cases by baseline RASs. In a 2-year follow-up, we analyzed viral markers and biochemical and hematological parameters of the participants and their sustained virologic response (SVR). Statistical analyses were performed using SPSS software version 22. RESULTS RASs for HCV subtype 1a included M28V, L31M, and H58P. For subtype 1b: L28M, R30Q, S24F, and C316N. And for subtype 3a: C316S, and S24F. In patients with cirrhosis (n = 5), ALT ( p = 0.001) and AST ( p = 0.007) levels were significantly reduced after treatment, and creatinine level slightly increased ( p = 0.025). However, no significant data was observed in non-cirrhotic patients following the treatment. CONCLUSION The present study did not show any adverse effects of DAA therapy among patients with thalassemia suffering from chronic HCV infection with baseline RASs. Furthermore, reduction in ferritin and liver stiffness levels after DAA therapy could show the efficacy of DAA in such patients.

show abstract